Market Overview on Helicobacter pylori Infections-Pipeline Review, H2 2016

Helicobacter pylori Infections-Pipeline Review, H2 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Helicobacter pylori Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Helicobacter pylori Infections, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Helicobacter pylori Infections and features dormant and discontinued projects.

Complete report available @ Helicobacter pylori Infections-Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Helicobacter pylori Infections
- The report reviews pipeline therapeutics for Helicobacter pylori Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Helicobacter pylori Infections therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Helicobacter pylori Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Helicobacter pylori Infections
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Daewoong Pharmaceutical Co., Ltd. Debiopharm International SA EpiVax, Inc. Frost Biologic, Inc. ImevaX GmbH ImmunoBiology Limited Recce Pty Ltd RedHill Biopharma Ltd. Sequella, Inc. Sigmoid Pharma Limited

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###